ArticleClinical and translational gastroenterology2016
Expression of Annexin A10 in Serrated Polyps Predicts the Development of Metachronous Serrated Polyps.
Article in Clinical and translational gastroenterology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Recommendations for Follow-Up After Colonoscopy and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer.The American journal of gastroenterology · 2020Guideline
- Trial
- Prediction of metachronous advanced colorectal neoplasia by KRAS mutation in polyps.United European gastroenterology journal · 2024Article
- Knockdown of ANXA10 induces ferroptosis by inhibiting autophagy-mediated TFRC degradation in colorectal cancer.Cell death & disease · 2023Article
- Sporadic hyperplastic polyp associated with above-average risk of developing metachronous colorectal cancer.American journal of cancer research · 2023Article
- The prognostic significance of annexin A family in glioblastoma.Irish journal of medical science · 2022Article
- Role of hospitalization for inflammatory bowel disease in the post-biologic era.World journal of clinical cases · 2021Review
- Article
- Annexin A10 is a novel prognostic biomarker of papillary thyroid cancer.Irish journal of medical science · 2021Article
- Recommendations for Follow-Up After Colonoscopy and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer.Gastrointestinal endoscopy · 2020Article
- Recommendations for Follow-Up After Colonoscopy and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer.Gastroenterology · 2020Article
- Traditional serrated adenoma: an overview of pathology and emphasis on molecular pathogenesis.BMJ open gastroenterology · 2019Review
- The Serrated Polyp Pathway: Is It Time to Alter Surveillance Guidelines?Current gastroenterology reports · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe ability to differentiate histological characteristics between serrated polyps (SPs) and make a pathological diagnosis of a sessile serrated polyp (SSP) is highly variable. Recent studies have shown that immunohistochemical (IHC) expression of Annexin A10 (ANXA10) is a marker of a SSP. However, the clinical utility of ANXA10 expression in patients with SPs is unknown. The objective of this study was to evaluate the utility of ANXA10 expression in SPs in predicting the development of subsequent polyps at follow-up colonoscopy.
methodsSpecimens from patients with SPs assessed in the Department of Pathology between 2006 and 2010 were identified. Patients whose colon harbored only SPs including either an SSP and/or hyperplastic polyp (HP) and who had complete polyp resection, no remaining polyps, and a follow-up colonoscopy were analyzed. ANXA10 IHC expression was performed in all baseline SPs. The rate of metachronous polyps on follow-up colonoscopy based on baseline maximal ANXA10 expression (low vs. high) was determined.
resultsOne hundred and seventy-nine patients were included. Sixty-seven patients had SPs with low ANXA10 expression (30 SSP and 37 HP) and 112 had polyps with high ANXA10 expression (105 SSP and 7 with HP). Individuals with SPs with high ANXA10 expression had a threefold higher risk of SSP on follow-up colonoscopy (hazard ratio (HR)=2.7; P=0.048) particularly, in the proximal colon (HR=4.0; P=0.02). ANXA10 expression did not predict patients at an increased risk of subsequent adenomas (18.8% vs. 19.4%, P=0.52).
conclusionsIndividuals who harbor SPs with high ANXA10 expression are at an increased risk of metachronous serrated neoplasms. ANXA10 may be a reproducible tool to stratify patients with SPs into higher- and lower-risk groups of metachronous serrated neoplasia, allowing a more aggressive colonoscopic surveillance in patients at high risk.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.